Phase 3 Alzheimer's drugs in development July 2019, by mechanism of action
Of the 26 drugs in phase three of clinical trials as of July 2019, 13 of them were drugs that target neurotransmitters in the brain such as acetylcholine and glutamate. This statistic depicts the number of Alzheimer's drugs in phase three of clinical trials, by mechanism of action.